Page 27 - CBAC Newsletter 2016

147. Friedel HA, Fitton A. Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain
148. states. Drugs. 45, 548-569, 1993.
149.
Gribkoff VK. The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin Ther Targets.
150. 7, 737-748, 2003.
151.
152. Seyfried J, Evert BO, Rundfeldt C, Schulz JB, Kovar KA, Klockgether T, Wullner U. Flupirtine and retigabine
153. prevent L-glutamate toxicity in rat pheochromocytoma PC 12 cells. Eur J Pharmacol.
400, 155-166, 2000.
154.
155. Ilyin VI, Carlin KP, Hodges DD, Robledo S, Woodward RM. Flupertine. A positive modulator of heteromeric
156. KCNQ2/Q3 channels. Soc Neurosci Abstr. 758, 2002.
157.
158. Noam Y, Raol YH, Holmes GL. Searching for new targets for treatment of pediatric epilepsy. Epilepsy Behav.
26, 253-260, 2013.
159.
160. Yu F, Liu YL, Wang YC, Yin J, Wang H, Liu WH, Peng BW, He XH. Protective effect of the KCNQ activator
161. flupirtine on a model of repetitive febrile seizures. Epilepsy Behav. 97, 64-72, 2011.

162. Li C, Huang P, Lu Q, Zhou M, Guo L, Xu X. KCNQ/Kv7 channel activator flupirtine protects against acute
163. stress-induced impairments of spatial memory retrieval and hippocampal LTP in rats. Neuroscience.
280, 19-30, 2014.
164.
165. Song M, Yu SP. Ionic regulation of cell volume changes and cell death after ischemic stroke.
166. Transl Stroke Res. 5, 17-27, 2014.

Zhou X, Wei J, Song M, Francis K, Yu SP. Novel role of KCNQ2/3 channels in regulating neuronal cell viability.
Cell Death Differ. 18, 493-505, 2011.

Richter A, Sander SE, Rundfeldt C. Antidystonic effects of Kv7 (KCNQ) channel openers in the dt sz mutant,
an animal model of primary paroxysmal dystonia. Br J Pharmacol. 149, 747-753, 2006.

Salata JJ, Jurkiewicz NK, Wang J, Evans BE, Orme HT, Sanguinetti MC. A novel benzodiazepine that activates
cardiac slow delayed rectifier K+ currents. Mol Pharmacol. 54, 220-230, 1998.

Chadha PS, Zunke F, Davis AJ, Jepps TA, Linders JT, Schwake M, Towart R, Greenwood IA. Pharmacological
dissection of K(v)7.1 channels in systemic and pulmonary arteries. Br J Pharmacol.
166, 1377-1387, 2012.

Tapper AR, George AL Jr. Location and orientation of minK within the I(Ks) potassium channel complex.
J Biol Chem. 276, 38249-38254, 2001.

Busch AE, Herzer T, Wagner CA, Schmidt F, Raber G, Waldegger S, Lang F. Positive regulation by chloride
channel blockers of IsK channels expressed in Xenopus oocytes. Mol Pharmacol. 46, 750-753, 1994.

Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, Attali B. Meclofenamic acid and diclofenac, novel
templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit
anticonvulsant properties. Mol Pharmacol. 67, 1053-1066, 2005.

Varnum MD, Busch AE, Maylie J, Adelman JP. Chemical Cross-Linking Induces Persistent Activation of Isk
Expressed in Xenopus Oocytes. Biophys J. 64, A198-A198, 1993.

Busch AE, Busch GL, Ford E, Suessbrich H, Lang HJ, Greger R, Kunzelmann K, Attali B, Stuhmer W. The role
of the IsK protein in the specific pharmacological properties of the IKs channel complex. Br J Pharmacol.
122, 187-189, 1997.

Abitbol I, Peretz A, Lerche C, Busch AE, Attali B. Stilbenes and fenamates rescue the loss of I(KS) channel
function induced by an LQT5 mutation and other IsK mutants. EMBO J. 18, 4137-4148, 1999.

Greenwood IA, Large WA. Comparison of the effects of fenamates on Ca-activated chloride and potassium
currents in rabbit portal vein smooth muscle cells. Br J Pharmacol. 116, 2939-2948, 1995.

Schnee ME, Brown BS. Selectivity of linopirdine (DuP 996), a neurotransmitter release enhancer, in blocking
voltage-dependent and calcium-activated potassium currents in hippocampal neurons.
J Pharmacol Exp Ther. 286, 709-717, 1998.

CBAC Center Heartbeat | 23